NCT02013622View on ClinicalTrials.gov

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

Brexpiprazole

Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally

Trial Locations (22)

14618

Rochester

19139

Philadelphia

30308

Atlanta

33334

Fort Lauderdale

38119

Memphis

60169

Hoffman Estates

70629

Lake Charles

75231

Dallas

75243

Dallas

77007

Houston

90502

Torrance

90660

Pico Rivera

90703

Cerritos

90806

Long Beach

92056

Oceanside

92102

San Diego

92105

Chula Vista

92123

San Diego

92506

Riverside

92626

Costa Mesa

92705

Santa Ana

94612

Oakland

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY